Related Experiment Video
Updated: Apr 7, 2026
Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
Published on: December 16, 2022
Rational Combination of Immunotherapies with Clinical Efficacy in Mice with Advanced Cancer
Ali Bransi1, Oscar Camilo Salgado1, Michal Beffinger1
1Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Abstract:
In the context of cancer, naïve T cells are insufficiently primed and become progressively dysfunctional. Boosting antitumor responses by blocking PD-1 or CTLA-4 results in durable clinical responses only in a limited proportion of cancer patients, suggesting that other pathways must be targeted to improve clinical efficacy. Our preclinical study in TRAMP mice comparing 14 different immune interventions identified anti-CD40 + IL2/anti-IL2 complexes + IL12Fc as a uniquely efficacious treatment that prevents tolerance induction, promotes priming of sustained, protective tumor-specific CD8(+) T cells, and cures late-stage cancer when given together with adoptively transferred tumor-specific T cells. We propose that improving signals 2 (costimulation) and 3 (cytokines) together with fresh tumor-specific, rather than boosting of dysfunctional preexisting memory, T cells represents a potent therapy for advanced cancer.
Insights
This study reveals a novel cancer immunotherapy combining anti-CD40, IL-2, and IL-12Fc. This approach effectively primes T cells and cures advanced cancer in mice, offering new hope for patients.
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- T cell dysfunction is a major hurdle in cancer immunity.
- Current immunotherapies like PD-1/CTLA-4 blockade benefit only a subset of patients.
- Targeting alternative pathways is crucial for improving cancer treatment efficacy.
Purpose of the Study:
- To identify novel immune interventions for advanced cancer.
- To evaluate combination therapies that enhance anti-tumor T cell responses.
- To overcome T cell tolerance and dysfunction in the tumor microenvironment.
Main Methods:
- Preclinical study in TRAMP mice model.
- Comparison of 14 different immune interventions.
- Assessment of T cell priming, function, and tumor eradication.
Main Results:
- A combination of anti-CD40, IL-2/anti-IL-2 complexes, and IL-12Fc demonstrated unique efficacy.
- This combination prevented immune tolerance and promoted sustained, tumor-specific CD8(+) T cell responses.
- The treatment cured late-stage cancer when combined with adoptive T cell transfer.
Conclusions:
- Enhancing co-stimulation (signal 2) and cytokine support (signal 3) is a potent strategy.
- Priming fresh tumor-specific T cells is more effective than boosting memory cells.
- This combination therapy holds promise for treating advanced cancers.
More Related Videos
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
12:42Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Related Concept Videos
01:27Tumor Immunotherapy
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...